{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,30]],"date-time":"2026-07-30T16:18:46Z","timestamp":1785428326557,"version":"3.56.0"},"reference-count":45,"publisher":"Centre for Evaluation in Education and Science (CEON\/CEES)","issue":"1","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/BY\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Med Biochemistry"],"published-print":{"date-parts":[[2025]]},"abstract":"<jats:p>Background: The SNP rs855791 has been linked to increased hepcidin levels, variations in serum iron, transferrin saturation and red blood cell indices. Our goal was to determine the prevalence of this polymorphism among COPD patients and to assess its impact on iron status parameters in patients with stable COPD. Methods: We analysed iron status parameters and genetic data from 29 COPD patients with wild-type genotype (WT group) and 65 COPD patients with either homozygous or heterozygous genotype (HH group). Additionally, the prevalence of SNP rs855791 was assessed in 192 volunteers. Results: The frequency distribution of SNP rs855791 was comparable between the COPD patients and control subjects (p=0.791). Iron status parameters were within their respective reference values and showed neither statistically nor clinically significant difference between the WT and HH group of COPD patients. However, after excluding patients with (sub)clinical vitamin B12 deficiency and\/or hypoxemia, WT group of patients exhibited significantly lower erythropoietin levels (p=0.015). The area under the curve for erythropoietin was 0.688 (95% CI: 0.545-0.830, p=0.015), with an optimal cut-off of 9.74, sensitivity of 61.2% (95% CI: 58.1-64.3) and specificity of 65.0% (95% CI: 61.8-68.3).Conclusions: Iron status parameters do not differ between WT and HH groups of stable COPD patients. Statistical but not clinical difference in EPO levels was observed in a subgroup of patients. In addition to promoting erythropoiesis, EPO may regulate hepcidin levels and thus influence the development of iron deficiency and\/or anaemia. Also, EPO's direct effect on immune cells and down-regulation of inflammatory reactions should be considered in this context.<\/jats:p>","DOI":"10.5937\/jomb0-52996","type":"journal-article","created":{"date-parts":[[2024,11,8]],"date-time":"2024-11-08T05:06:16Z","timestamp":1731042376000},"page":"129-140","source":"Crossref","is-referenced-by-count":0,"title":["Influence of TMPRSS6 genotype on iron status parameters in stable COPD patients"],"prefix":"10.5937","volume":"44","author":[{"given":"Marko","family":"Trtica","sequence":"first","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02qsmb048","id-type":"ROR","asserted-by":"publisher"}]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0202-0673","authenticated-orcid":false,"given":"Ivana","family":"Novakovi\u0107","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02qsmb048","id-type":"ROR","asserted-by":"publisher"}]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8310-6254","authenticated-orcid":false,"given":"Violeta","family":"Dopsaj","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02qsmb048","id-type":"ROR","asserted-by":"publisher"}]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0767-6869","authenticated-orcid":false,"given":"Branislava","family":"Milenkovi\u0107","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02qsmb048","id-type":"ROR","asserted-by":"publisher"}]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8529-8624","authenticated-orcid":false,"given":"Jelena","family":"Jankovi\u0107","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02qsmb048","id-type":"ROR","asserted-by":"publisher"}]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9989-3862","authenticated-orcid":false,"given":"Sanja","family":"Dimi\u0107-Janji\u0107","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02qsmb048","id-type":"ROR","asserted-by":"publisher"}]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vesna","family":"Dopu\u0111a-Panti\u0107","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/00rrer658","id-type":"ROR","asserted-by":"publisher"}]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jelena","family":"Martinovi\u0107","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6878-8645","authenticated-orcid":false,"given":"Sne\u017eana","family":"Jovi\u010di\u0107","sequence":"additional","affiliation":[{"id":[{"id":"https:\/\/ror.org\/02qsmb048","id-type":"ROR","asserted-by":"publisher"}]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"3964","reference":[{"key":"ref1","doi-asserted-by":"crossref","unstructured":"Vestbo J, Hurd SS, Agust\u00ed AG, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease GOLD executive summary. Am J Respir Crit Care Med 2013; 187(4): 347-65. doi:10.1164\/rccm.201204-0596PP;","DOI":"10.1164\/rccm.201204-0596PP"},{"key":"ref2","doi-asserted-by":"crossref","unstructured":"Hoepers AT de C, Menezes MM, Fr\u00f6de TS. Systematic review of anaemia and inflammatory markers in chronic obstructive pulmonary disease. Clin Exp Pharmacol Physiol 2015; 42(3): 231-9. doi:10.1111\/1440-1681.12357;","DOI":"10.1111\/1440-1681.12357"},{"key":"ref3","doi-asserted-by":"crossref","unstructured":"Boutou AK, Pitsiou GG, Stanopoulos I, Kontakiotis T, Kyriazis G, Argyropoulou P. Levels of inflammatory mediators in chronic obstructive pulmonary disease patients with anemia of chronic disease: A case-control study. Qjm 2012; 105(7): 657-63. doi:10.1093\/qjmed\/ hcs024;","DOI":"10.1093\/qjmed\/hcs024"},{"key":"ref4","doi-asserted-by":"crossref","unstructured":"Boutou AK, Stanopoulos I, Pitsiou GG, et al. Anemia of chronic disease in chronic obstructive pulmonary disease: A case-control study of cardiopulmonary exercise responses. Respiration 2011; 82(3): 237-45. doi:10.1159\/000326899;","DOI":"10.1159\/000326899"},{"key":"ref5","doi-asserted-by":"crossref","unstructured":"Cloonan SM, Mumby S, Adcock IM, Choi AMK, Chung KF, Quinlan GJ. The iron-y of iron overload and iron deficiency in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2017; 196(9): 1103-12. doi:10.1164\/rccm.201702-0311PP;","DOI":"10.1164\/rccm.201702-0311PP"},{"key":"ref6","doi-asserted-by":"crossref","unstructured":"DeMeo DL, Mariani T, Bhattacharya S, et al. Integration of Genomic and Genetic Approaches Implicates IREB2 as a COPD Susceptibility Gene. Am J Hum Genet 2009; 85(4): 493-502. doi:10.1016\/j.ajhg.2009.09.004;","DOI":"10.1016\/j.ajhg.2009.09.004"},{"key":"ref7","doi-asserted-by":"crossref","unstructured":"Chappell SL, Daly L, Lotya J, et al. The role of IREB2 and transforming growth factor beta-1 genetic variants in COPD: a replication case-control study. BMC Med Genet 2011; 12. doi:10.1186\/1471-2350-12-24;","DOI":"10.1186\/1471-2350-12-24"},{"key":"ref8","doi-asserted-by":"crossref","unstructured":"Hardin M, Zielinski J, Wan ES, et al. CHRNA3\/5, IREB2, and ADCY2 are associated with severe chronic obstructive pulmonary disease in Poland. Am J Respir Cell Mol Biol 2012; 47(2): 203-8. doi:10.1165\/rcmb.2012-0011OC;","DOI":"10.1165\/rcmb.2012-0011OC"},{"key":"ref9","doi-asserted-by":"crossref","unstructured":"Robalo Nunes, A., T\u00e1t\u00e1 M. The impact of anaemia and iron deficiency in chronic obstructive pulmonary disease: A clinical overview. Revista Portuguesa de Pneumologia (English Edition) 2017; 23(3): 146-55. doi:10.1016 \/j.rppnen.2016.12.005;","DOI":"10.1016\/j.rppnen.2016.12.005"},{"key":"ref10","doi-asserted-by":"crossref","unstructured":"Markoulaki D, Kostikas K, Papatheodorou G, et al. Hemo globin, erythropoietin and systemic inflammation in exacerbations of chronic obstructive pulmonary disease. Eur J Intern Med 2011; 22(1): 103-7. doi:10.1016\/j.ejim.2010.07.010;","DOI":"10.1016\/j.ejim.2010.07.010"},{"key":"ref11","doi-asserted-by":"crossref","unstructured":"Tandara L, Grubisic TZ, Ivan G, et al. Systemic inflammation up-regulates serum hepcidin in exacerbations and stabile chronic obstructive pulmonary disease. Clin Biochem 2015; 48(18): 1252-7. doi:10.1016\/j.clinbiochem.2015.07.010;","DOI":"10.1016\/j.clinbiochem.2015.07.010"},{"key":"ref12","doi-asserted-by":"crossref","unstructured":"Portillo K, Martinez-Rivera C, Ruiz-Manzano J. Anaemia in chronic obstructive pulmonary disease. Does it really matter? Int J Clin Pract 2013; 67(6): 558-65. doi:10.1111\/ijcp.12125;","DOI":"10.1111\/ijcp.12125"},{"key":"ref13","doi-asserted-by":"crossref","unstructured":"Archer NM, Brugnara C. Diagnosis of iron-deficient states. Crit Rev Clin Lab Sci 2015; 52(5): 256-72. doi:10.3109\/10408363.2015.1038744;","DOI":"10.3109\/10408363.2015.1038744"},{"key":"ref14","doi-asserted-by":"crossref","unstructured":"Silverberg DS, Mor R, Weu MT, Schwartz D, Schwartz IF, Chernin G. Anemia and iron deficiency in COPD patients: Prevalence and the effects of correction of the anemia with erythropoiesis stimulating agents and intravenous iron. BMC Pulm Med 2014; 14(1): 38-42. doi:10.1186\/1471-2466-14-24;","DOI":"10.1186\/1471-2466-14-24"},{"key":"ref15","doi-asserted-by":"crossref","unstructured":"Ganz T, Nemeth E, Rivella S, et al. TMPRSS6 as a Therapeutic Target for Disorders of Erythropoiesis and Iron Homeostasis. Adv Ther 2023; 40(4): 1317-333. doi:10.1007\/s12325-022-02421-w;","DOI":"10.1007\/s12325-022-02421-w"},{"key":"ref16","doi-asserted-by":"crossref","unstructured":"Nai A, Pagani A, Silvestri L, et al. TMPRSS6 rs855791 modulates hepcidin transcription in vitro and serum hepcidin levels in normal individuals. Blood 2011; 118(16): 4459-62. doi:10.1182\/blood-2011-06-364034;","DOI":"10.1182\/blood-2011-06-364034"},{"key":"ref17","doi-asserted-by":"crossref","unstructured":"Jallow MW, Cerami C, Clark TG, Prentice AM, Campino S. Differences in the frequency of genetic variants associated with iron imbalance among global populations. PLoS One 2020; 15(7). doi:10.1371\/journal. pone.0235141;","DOI":"10.1371\/journal.pone.0235141"},{"key":"ref18","doi-asserted-by":"crossref","unstructured":"Chambers JC, Zhang W, Li Y, et al. Genome-wide association study identifies variants in TMPRSS6 associated with hemoglobin levels. Nat Genet 2009; 41(11): 1170-2. doi:10.1038\/ng.462;","DOI":"10.1038\/ng.462"},{"key":"ref19","doi-asserted-by":"crossref","unstructured":"Benyamin B, Ferreira MAR, Willemsen G, et al. Common variants in TMPRSS6 are associated with iron status and erythrocyte volume. Nat Genet 2009; 41(11): 1173-5. doi:10.1038\/ng.456;","DOI":"10.1038\/ng.456"},{"key":"ref20","doi-asserted-by":"crossref","unstructured":"Pelusi S, Girelli D, Rametta R, et al. The A736V TMPRSS6 polymorphism influences hepcidin and iron metabolism in chronic hemodialysis patients: TMPRSS6 and hepcidin in hemodialysis. BMC Nephrol 2013; 14(1). doi:10.1186\/1471-2369-14-48;","DOI":"10.1186\/1471-2369-14-48"},{"key":"ref21","doi-asserted-by":"crossref","unstructured":"Nickol AH, Frise MC, Cheng HY, et al. A cross-sectional study of the prevalence and associations of iron deficiency in a cohort of patients with chronic obstructive pulmonary disease. BMJ Open 2015; 5(7): 1-10. doi:10.1136\/bmjopen-2015-007911;","DOI":"10.1136\/bmjopen-2015-007911"},{"key":"ref22","doi-asserted-by":"crossref","unstructured":"Girelli D, Nemeth E, Swinkels DW. Hepcidin in the diagnosis of iron disorders. Blood 2016; 127(23): 2809-13. doi:10.1182\/blood-2015-12-639112;","DOI":"10.1182\/blood-2015-12-639112"},{"key":"ref23","unstructured":"Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease; 2020. www.goldcopd.org;"},{"key":"ref24","unstructured":"Yun JH LACR et al. Blood eosinophil thresholds and exacerbations in chronic obstructive pulmonary disease. J Allergy Clin Immunol 2018; 141(6): 2037-47. doi:10.1016\/j.jaci.2018.04.010;"},{"key":"ref25","doi-asserted-by":"crossref","unstructured":"Milenkovi\u0107 B, Janji\u0107 SD, Kotur-Stevuljevi\u0107 J, et al. Validation of Serbian version of chronic obstructive pulmonary disease assessment test. Vojnosanit Pregl 2020; 77(3): 294-9. doi:10.2298\/VSP180220094M;","DOI":"10.2298\/VSP180220094M"},{"key":"ref26","doi-asserted-by":"crossref","unstructured":"Lee H, Um SJ, Kim YS, et al. Association of the neutrophil-to-lymphocyte ratio with lung function and exacerbations in patients with chronic obstructive pulmonary disease. PLoS One 2016; 11(6): 1-13. doi:10.1371\/ journal.pone.0156511;","DOI":"10.1371\/journal.pone.0156511"},{"key":"ref27","doi-asserted-by":"crossref","unstructured":"Jo YS, Yoon H Il, Kim DK, Yoo CG, Lee CH. Comparison of COPD assessment test and clinical COPD questionnaire to predict the risk of exacerbation. International Journal of COPD. 2018; 13. doi:10.2147\/COPD. S149805;","DOI":"10.2147\/COPD.S149805"},{"key":"ref28","unstructured":"WHO Haemoglobin concentrations for the diagnosis of anaemia and assessment of severity Vitamin and Mineral Nutrition Information System Geneva, World Health Organization, 2011 (WHO\/NMH\/NHD\/MNM\/111) (http:\/\/www.who.int\/vmnis\/indicators\/haemoglobin pdf. Published online 2019;"},{"key":"ref29","doi-asserted-by":"crossref","unstructured":"Jones PW, Tabberer M, Chen WH. Creating scenarios of the impact of copd and their relationship to copd assessment test (CATTM) scores. BMC Pulm Med 2011; 11. doi:10.1186\/1471-2466-11-42;","DOI":"10.1186\/1471-2466-11-42"},{"key":"ref30","doi-asserted-by":"crossref","unstructured":"Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD Assessment Test. European Respiratory Journal 2009; 34(3): 648-54. doi:10.1183\/09031936. 00102509;","DOI":"10.1183\/09031936.00102509"},{"key":"ref31","doi-asserted-by":"crossref","unstructured":"Kon SSC, Canavan JL, Jones SE, et al. Minimum clinically important difference for the COPD Assessment Test: A prospective analysis. Lancet Respir Med 2014; 2(3): 195-203. doi:10.1016\/S2213-2600(14)70001-3;","DOI":"10.1016\/S2213-2600(14)70001-3"},{"key":"ref32","unstructured":"Beckman Coulter Inc. Access Vitamin B12 Instructions For Use Cobalamin REF 33000.; 2020;"},{"key":"ref33","doi-asserted-by":"crossref","unstructured":"Kroot JJC, Tjalsma H, Fleming RE, Swinkels DW. Hepcidin in human iron disorders: Diagnostic implications. Clin Chem 2011; 57(12): 1650-69. doi:10.1373\/clinchem.2009.140053;","DOI":"10.1373\/clinchem.2009.140053"},{"key":"ref34","doi-asserted-by":"crossref","unstructured":"Zhang J, DeMeo DL, Silverman EK, et al. Secondary polycythemia in chronic obstructive pulmonary disease: prevalence and risk factors. BMC Pulm Med 2021; 21(1): 1-12. doi:10.1186\/s12890-021-01585-5;","DOI":"10.1186\/s12890-021-01585-5"},{"key":"ref35","doi-asserted-by":"crossref","unstructured":"Solmaz S, \u00d6zdo u H, Bo a C. Cobalamin Deficiency Can Mask Depleted Body Iron Reserves. Indian Journal of Hematology and Blood Transfusion 2015; 31(2): 255-8. doi:10.1007\/s12288-014-0417-x;","DOI":"10.1007\/s12288-014-0417-x"},{"key":"ref36","doi-asserted-by":"crossref","unstructured":"Ghio AJ, Roggli VL, Soukup JM, Richards JH, Randell SH, Muhlebach MS. Iron accumulates in the lavage and explanted lungs of cystic fibrosis patients. Journal of Cystic Fibrosis 2013; 12(4): 390-8. doi:10.1016\/j.jcf. 2012.10.010;","DOI":"10.1016\/j.jcf.2012.10.010"},{"key":"ref37","doi-asserted-by":"crossref","unstructured":"Ghio AJ. Disruption of iron homeostasis and lung disease. Biochim Biophys Acta Gen Subj 2009; 1790(7): 731-9. doi:10.1016\/j.bbagen.2008.11.004;","DOI":"10.1016\/j.bbagen.2008.11.004"},{"key":"ref38","doi-asserted-by":"crossref","unstructured":"Neves J, Leitz D, Kraut S, et al. Disruption of the Hep - cidin\/Ferroportin Regulatory System Causes Pulmonary Iron Overload and Restrictive Lung Disease. EBioMedicine 2017; 20: 230-9. doi:10.1016\/j.ebiom. 2017.04.036;","DOI":"10.1016\/j.ebiom.2017.04.036"},{"key":"ref39","doi-asserted-by":"crossref","unstructured":"Dopsaj V, Topi\u0107 A, Savkovi\u0107 M, et al. Associations of common variants in HFE and TMPRSS6 genes with hepcidin-25 and iron status parameters in patients with end-stage renal disease. Dis Markers 2019; 2019(Id). doi:10.1155\/2019\/4864370;","DOI":"10.1155\/2019\/4864370"},{"key":"ref40","doi-asserted-by":"crossref","unstructured":"Gammella E, Diaz V, Recalcati S, et al. Erythropoietin's inhibiting impact on hepcidin expression occurs indirectly. Am J Physiol Regul Integr Comp Physiol 2015; 308: 330-5. doi:10.1152\/ajpregu.00410.2014;","DOI":"10.1152\/ajpregu.00410.2014"},{"key":"ref41","doi-asserted-by":"crossref","unstructured":"Peng H, Truksa J, Lee P. EPO-mediated reduction in Hamp expression in vivo corrects iron deficiency anaemia in TMPRSS6 deficiency. Br J Haematol 2010; 151(1): 106-9. doi:10.1111\/j.1365-2141.2010.08306.x;","DOI":"10.1111\/j.1365-2141.2010.08306.x"},{"key":"ref42","doi-asserted-by":"crossref","unstructured":"Peng B, Kong G, Yang C, Ming Y. Erythropoietin and its derivatives: from tissue protection to immune regulation. Cell Death Dis 2020; 11(2). doi:10.1038\/s41419-020-2276-8;","DOI":"10.1038\/s41419-020-2276-8"},{"key":"ref43","doi-asserted-by":"crossref","unstructured":"Karlsson T. Evaluation of a competitive hepcidin ELISA assay in the differential diagnosis of iron deficiency anaemia with concurrent inflammation and anaemia of inflammation in elderly patients. Journal of Inflammation (United Kingdom). 2017; 14(1). doi:10.1186\/s12950-017-0166-3;","DOI":"10.1186\/s12950-017-0166-3"},{"key":"ref44","doi-asserted-by":"crossref","unstructured":"Kroot JJC, Laarakkers CMM, Geurts-Moespot AJ, et al. Immunochemical and mass-spectrometry-based serum hepcidin assays for iron metabolism disorders. Clin Chem 2010; 56(10): 1570-9. doi:10.1373\/clinchem.2010. 149187;","DOI":"10.1373\/clinchem.2010.149187"},{"key":"ref45","doi-asserted-by":"crossref","unstructured":"Camaschella C, Nai A, Silvestri L. Iron metabolism and iron disorders revisited in the hepcidin era. Haemato lo - gica 2020; 105(2): 260-72. doi:10.3324\/haematol. 2019.232124;","DOI":"10.3324\/haematol.2019.232124"}],"container-title":["Journal of Medical Biochemistry"],"original-title":["Uticaj TMPRSS6 genotipova na parametre statusa gvo\u017e\u0111a kod pacijenata sa stabilnim oblikom HOBP"],"language":"en","link":[{"URL":"https:\/\/aseestant.ceon.rs\/index.php\/jomb\/article\/download\/52996\/26307","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/scindeks-clanci.ceon.rs\/data\/pdf\/1452-8258\/2025\/1452-82582501129T.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,24]],"date-time":"2025-01-24T02:24:51Z","timestamp":1737685491000},"score":1,"resource":{"primary":{"URL":"https:\/\/scindeks.ceon.rs\/Article.aspx?artid=1452-82582501129T"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025]]},"references-count":45,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.5937\/jomb0-52996","relation":{},"ISSN":["1452-8258","1452-8266"],"issn-type":[{"value":"1452-8258","type":"print"},{"value":"1452-8266","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025]]}}}